# Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide

Source: https://onco.cc/trials/nct02815033/  
OnCo record `nct02815033` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed.

## Summary

Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide is a phase 2 interventional study registered as NCT02815033 by The European Uro-Oncology Group, with 66 participants recorded, started 2015-07 and reaching its primary completion in 2020-06. Interventions recorded: Enzalutamide, 11C or 18F-Choline PET/CT, Whole body MRI, Bone scan. Conditions recorded: Prostate Cancer Metastatic.

Linked to the technology Whole-body MRI because the registry names it ("whole body mri") among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02815033
- Phase: 2
- Setting: An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients)
- Sponsor: The European Uro-Oncology Group
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT02815033: https://clinicaltrials.gov/study/NCT02815033

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Whole-body MRI](https://onco.cc/technologies/whole-body-mri/)
- drugs: [Enzalutamide](https://onco.cc/drugs/enzalutamide/)

---
JSON: https://onco.cc/api/v1/entities/nct02815033.json